Heretic
Guide

Longevity science

What actually moves the needle on aging: exercise and sleep by a mile, with drugs still stuck at biomarker-level proof.

Updated 14 Oct 202618 sources15 min read
Short answer

Longevity science targets the biological processes of aging itself, organized around the 12 hallmarks framework. The evidence pyramid is clear: exercise, sleep, diet and social connection have the strongest mortality data, while pharmaceuticals like rapamycin and metformin show safety and biomarker signals but nothing on human lifespan or healthspan endpoints. The best human trials so far, PEARL for rapamycin and TRIIM for epigenetic-age reversal, are small, short and surrogate-based.

Summary drafted from this entry’s sources; editorial review pending.

01Key questions

Can anything slow human aging?

Nothing is proven. Exercise is the closest thing: cardiorespiratory fitness and grip strength are among the strongest predictors of all-cause mortality, while drugs like rapamycin have shown only safety and biomarker changes in small trials.347

Does rapamycin work for longevity?

Not proven. The 48-week PEARL trial found it safe with modest benefits in women, and RAPA-EX-01 flagged that it blunted exercise-driven muscle growth. Trials measure biomarkers, not lifespan.78

What about metformin for aging?

The case rests on observational data that a 2025 review questioned, and the definitive TAME trial of 3,000 people is still not recruited.918

What are biological age clocks?

DNA-methylation scores estimating biological rather than chronological age. GrimAge predicts mortality best and DunedinPACE measures rate of aging, but clocks often disagree about the same intervention.12131415

What would change this rating?

A human trial showing a drug slows aging on a clinical endpoint. TAME is designed for exactly that but remains pre-recruitment.18

Aging is not inevitable — it is a biological process with identifiable mechanisms that can be modulated. The "hallmarks of aging" framework identifies 12 interconnected processes that drive biological decline. Interventions targeting these hallmarks — from rapamycin to dietary patterns to senescent cell clearance — are moving from animal studies into human clinical trials. As of 2026, four pillars of human longevity RCT evidence have matured: PEARL (rapamycin), TAME (metformin, still pre-recruitment), TRIIM-X (epigenetic reprogramming cocktail), and a wave of biological-age-clock reversal trials.

02The Aging Problem

Lifespan vs. Healthspan

  • Lifespan: Total years alive. Has increased dramatically (from ~47 in 1900 to ~79 in 2024 in the US)
  • Healthspan: Years lived in good health. Has NOT kept pace — ~10-15 years of disability precede death for most
  • The goal is NOT immortality — it's compressing morbidity into the shortest possible period at the end of life ("compression of morbidity" — Fries 1980; JAMA PMID 6773612)

The Economics of Aging

  • Chronic disease accounts for ~90% of US healthcare spending ($4.5 trillion/year, CDC 2024)
  • The pharmaceutical industry profits from managing (not curing) age-related disease
  • This creates perverse incentives against prevention and longevity research
  • The 2024 US National Strategy to Support Family Caregivers estimates informal caregiving costs at ~$470B/year if paid

03The Hallmarks of Aging (2023 Update + 2024 Commentary)

The current 12-hallmark taxonomy was published by López-Otín, Blasco, Partridge, Serrano, Kroemer in Cell 2023 (PMID 36599349). It expands the original 2013 framework with three new hallmarks: disabled macroautophagy, chronic inflammation (inflammaging), and dysbiosis.

# Hallmark Description Key Intervention
1 Genomic instability DNA damage accumulation NAD+ optimization, DNA repair support
2 Telomere attrition Chromosome end shortening Telomerase activation
3 Epigenetic alterations DNA methylation changes Peptide bioregulators, reprogramming factors
4 Loss of proteostasis Protein misfolding/aggregation Autophagy induction
5 Deregulated nutrient sensing mTOR/AMPK dysregulation Rapamycin, metformin
6 Mitochondrial dysfunction Declining energy production CoQ10, NAD+, exercise
7 Cellular senescence "Zombie cells" that secrete inflammatory factors Dasatinib+quercetin, fisetin
8 Stem cell exhaustion Declining regenerative capacity Stem cell therapy
9 Altered intercellular communication Inflammatory signaling (SASP) Anti-inflammatory protocols
10 Disabled macroautophagy Impaired cellular recycling Fasting, spermidine
11 Chromatin reorganization Nuclear architecture changes Under investigation
12 Inflammaging + Dysbiosis Chronic low-grade inflammation + microbiome shift Anti-inflammatory, diet, probiotics

Swipe table →

2024 follow-up commentary (Tartiere, Freije, López-Otín, Front Aging 5:1334261) emphasizes that the 12 hallmarks should be viewed as interdependent rather than independent — e.g., senescent cells drive inflammaging, which accelerates epigenetic drift. A Copenhagen 2022 summary (Schmauck-Medina et al., Aging 14:6829) proposed additional candidates: altered mechanical properties, splicing dysregulation. None have been formally adopted.

For the deep-dive canonical reference, see Hallmarks of Aging - Canonical Framework — 21KB, primary-source PMIDs for each hallmark, 2024 Tartière/Freije/López-Otín evaluation of new candidates, hierarchical organization, cross-species validation evidence, and connection to all library topic pages.

04The Longevity Intervention Hierarchy (Updated 2026)

Tier 1: Lifestyle (Strongest Evidence, Highest Return)

  1. Exercise — VO2max and grip strength are the strongest predictors of all-cause mortality (Mandsager et al. JAMA Netw Open 2018, PMID 30646320; Kodama et al. JAMA 2009, PMID 19349377)
  2. Sleep — 7-9 hours, circadian alignment; short sleep associated with ~12% increased all-cause mortality (Cappuccio et al. Sleep 2010, PMID 20469800)
  3. Nutrition — Species-appropriate, metabolically healthy; Mediterranean diet has Class I evidence for cardiovascular and cognitive endpoints
  4. Fasting/Time-restricted eating — Autophagy activation, insulin reduction
  5. Social connection and purpose — Holt-Lunstad meta-analyses (2010, PLoS Med PMID 20668659) show social isolation is equivalent to smoking 15 cigarettes/day in mortality risk

Tier 2: Supplements (Moderate Evidence)

  1. NAD+ precursors (NMN/NR) — see also NAD+ Precursors and Telomere Biology - Evidence Audit
  2. Vitamin D3, magnesium, omega-3, creatine
  3. Spermidine, urolithin A — autophagy and mitophagy inducers with human biomarker data
  4. CoQ10, PQQ, alpha-lipoic acid

Tier 3: Pharmaceutical (Growing Evidence)

  1. Rapamycin — best-characterized human longevity drug. PEARL RCT (Moel et al. Aging 2025, PMID 40188830) showed 48-week safety + lean mass/pain signals in women at 5–10 mg weekly. RAPA-EX-01 (Stanfield et al. J Cachexia Sarcopenia Muscle 2026, PMID 41985884) flagged a key caveat: 6 mg/week attenuated exercise-induced hypertrophy in older adults.
  2. Metformin — AMPK activation, TAME trial (Barzilai et al., planned 3000 subjects, still pre-recruitment as of Aug 2026 per AFAR); 2025 critical review (Keys et al. Ageing Res Rev PMID 40582648) questions strength of observational evidence
  3. Low-dose lithium — epidemiological longevity data (Kessing et al. Br J Psychiatry 2008); small RCT signals in mild cognitive impairment
  4. Senolytic protocols (D+Q, fisetin) — first human senolytic trial: Justice et al. EBioMedicine 2019 (PMID 30678418) showed D+Q reduced senescent cells in idiopathic pulmonary fibrosis patients

Tier 4: Advanced/Experimental

  1. Telomerase activation (TA-65, epitalon)
  2. Stem cell therapies
  3. Plasma exchange / parabiosis factors — limited human data; Borsky et al. 2025 found 4–8 rounds of plasmapheresis increased DunedinPACE and GrimAge, contrary to the original Conboy mouse parabiosis hypothesis (PMID: see Front Genet 2026 review)
  4. Partial epigenetic reprogramming — see Partial Epigenetic Reprogramming - Competitive Intelligence. The TRIIM-X trial (2025, ongoing, completion Dec 2025) reported interim 20% increase in physical fitness and reduced body fat using a growth-hormone / DHEA / metformin cocktail originally piloted as the TRIIM trial (Fahy et al. Aging Cell 2019, PMID 30676660), which showed 1.5–2.5 years epigenetic age reversal on GrimAge.
  5. Gene therapy approaches

05Key Concepts in Longevity Science

Biological Age vs. Chronological Age

  • Epigenetic clocks now span four generations:
  • 1st gen (chronological): Horvath 2013 (PMID 24138928), Hannum 2013 (PMID 24138928)
  • 2nd gen (mortality-trained): PhenoAge (Levine 2018, PMID 29676998), GrimAge (Lu 2019, PMID 30669119), GrimAge2
  • 3rd gen (pace): DunedinPACE (Belsky 2022, PMID 35021509) — measures rate of aging
  • 4th gen (causal): AdaptAge, CausAge, DamAge (Yan et al. 2024–25)
  • GrimAge remains the most predictive single static estimator of mortality
  • DunedinPACE is now preferred for intervention trials because it captures change over short intervals
  • Biological age can differ from chronological age by ±10-20 years; modifiable

The Longevity Escape Velocity Concept

  • Proposed by Aubrey de Grey: If we can extend healthspan faster than time passes, we reach "escape velocity"
  • Each year of life, medical advances add more than one year of healthspan
  • Controversial but not physically impossible; requires sustained ~20% per-decade healthspan improvement

The Dogma of "Aging as Disease"

  • WHO ICD-11 lists "aging-associated decline" as an extension code (XT9T) — not a primary disease
  • US FDA does not recognize aging as an indication (5-year precedent: rejected BioAge/Altos Longevity submissions)
  • If aging were reclassified, reimbursement pathways and trial design would change dramatically
  • The TAME trial is structured to establish precedent for aging as a composite endpoint (cardiovascular events + cancer + dementia + mortality)

06Human Trial Evidence — Snapshot, September 2026

Trial Intervention Status Key Result Source
PEARL Rapamycin 5/10 mg weekly, 48 wk Completed 2025 Safe; women: ↑ lean mass, ↓ pain Moel et al., PMID 40188830
RAPA-EX-01 Sirolimus 6 mg/wk + exercise, 16 wk April 2026 Safety OK; attenuated hypertrophy Stanfield et al., PMID 41985884
TRIIM GH + DHEA + metformin, 1 yr Completed 2019 GrimAge ↓1.5–2.5 yr Fahy et al., PMID 30676660
TRIIM-X Same + lifestyle, larger cohort Ongoing, est. Dec 2025 Interim: ↑ fitness, ↓ fat Drug Discov World Nov 2025
TAME Metformin, 3000 subjects, 6 yr Pre-recruitment, partial funding — AFAR 2026
EVEROLIMUS (Mannick) mTOR inhibition in elderly Completed 2014, 2018 ↑ immune response to flu vaccine Mannick et al., PMID 25215462
First senolytic (D+Q) Senolytic in IPF Completed 2019 Improved 6-min walk, chair-stands Justice et al., PMID 30678418
Semaglutide + HIV lipohypertrophy GLP-1 RA Preprint 2025 Slowed epigenetic aging Corley et al. 2025 medRxiv
Bezisterim (NS-1/3) p38 MAPK in early AD 2025 ↓ biological age acceleration Reading et al., Front Neurosci 2025

Swipe table →

07Cross-Cutting Caveats (2024-2026 Findings)

  1. Exercise interaction: mTORC1 inhibitors taken close to resistance training blunt hypertrophy (RAPA-EX-01, PMID 41985884). Proposed workaround: 3–6-week interdose intervals.
  2. Clock interpretation: Multiple clocks (DunedinPACE, PC GrimAge, PhenoAge) often disagree on the same intervention (Frontiers in Genetics 2026 review). Trust directional concordance, not single-clock p-values.
  3. Plasmapheresis negative signal: Borsky et al. 2025 showed increased aging pace — murine parabiosis benefit does not translate.
  4. Rapamycin formulation bioavailability: Compounded rapamycin in PEARL had ~⅓ bioavailability of branded sirolimus — the dose actually delivered was lower than labeled.
  5. Cohort effects: Longevity-trial volunteers (PEARL, TRIIM) are health-conscious, well-educated, baseline low-burden — generalizability to typical aging populations is limited.

08Longevity and Anti-Aging — Index

The science of extending healthspan — compressing morbidity and optimizing the aging process itself. This section covers the hallmarks of aging, intervention mechanisms, the evidence for pharmaceutical and nutraceutical approaches, and practical protocols for targeting biological aging.

Why Longevity Science Has Transformed

Aging is the primary driver of chronic disease:

Disease Age as Primary Risk Factor
Heart disease #1 cause of death; risk doubles each decade after 45
Cancer Exponential increase with age; median diagnosis age 66
Neurodegeneration Alzheimer's, Parkinson's — strongly age-dependent
Type 2 diabetes Age + metabolic dysfunction; often reversible
Sarcopenia 3-8% muscle loss per decade after 30

Swipe table →

The longevity field has shifted from "anti-aging" (a cosmetic framing) to targeting aging biology itself as the root cause of multiple chronic diseases simultaneously:

  • 不再是"抗衰老" — Now "targeting the biology of aging" as a disease-modifying strategy
  • Clinical trials emerging — Senolytics, rapamycin, metformin, GLP-1 agonists
  • Biomarkers validated — Epigenetic clocks (Horvath, GrimAge), glycolytic shift markers
  • Investment surge — Altos Labs, Calico, Unity Biotechnology, multiple longevity biotech IPOs
  • Regulatory recognition — FDA considering "aging" as an indication for drug approval

The Goal: Healthspan, Not Just Lifespan

The target is not maximum lifespan (the record, Jeanne Calment at 122) but healthspan: - More years in good health - Reduced disability and disease - Maintained function and vitality - Compressed morbidity at end of life

The difference between lifespan and healthspan in developed nations is often 10-15 years of morbidity. Closing this gap is the central goal.

Foundational

File Description Status Size
Overview - Longevity Science Hallmarks of aging, intervention hierarchy, biological frameworks Good 5.8KB
Hallmarks of Aging - Canonical Framework Canonical 12-hallmark deep-dive — 2013/2023 evolution, 2024 Tartière evaluation, three criteria, hierarchical organization, candidate hallmarks rejected, cross-references Excellent 21.3KB
NAD+ IV Therapy NAD+ pharmacokinetics, IV vs. oral precursors, clinical evidence Excellent 21.8KB
Biological Age Clocks - Measurement and Interpretation Clock generations, Dec 2025–Mar 2026 validation trilogy, intervention ledger, testing guide Excellent 10.4KB

Swipe table →

Intervention Pillars

File Description Status Size
Autophagy Cellular recycling mechanism, activation strategies, disease applications Good 4.6KB
Metformin and Rapamycin Leading pharmaceutical longevity candidates; TAME trial Excellent 13.7KB
NAD+ and Sirtuin Activators NAD+ decline, NMN/NR supplementation, sirtuin science Good 5.5KB
Senolytics Clearing senescent "zombie" cells: D+Q, fisetin, quercetin Good 4.9KB
Telomere Science Telomere biology, telomerase activation, epitalon evidence Good 5.1KB
SGLT2 Inhibitors as Senotherapeutics Anti-diabetic drug class with anti-senescence biology; first drug RCT to lengthen human telomeres (henagliflozin 2025); honest risk ledger incl. female-mouse lifespan reduction Excellent 9.2KB
mTOR and AMPK Pathways The growth/repair metabolic master switches Good 5.9KB
Klotho - The Longevity Hormone Longevity hormone: biology, mortality associations, primate cognition data, gene-therapy pipeline Excellent 11.9KB
Taurine - The Aging Amino Acid Age-related decline hypothesis refuted by 2025 NIA longitudinal study; hormetic supplementation (1.5–4 g/day) trials (TauAge/TOP), NLRP3 mechanism, cardiometabolic meta-analyses Excellent 22.8KB

Swipe table →

Hallmarks of Aging — The Intervention Framework

The nine hallmarks of aging (López-Otín et al., 2013; updated 2023) provide the primary organizing framework for longevity interventions. Each hallmark represents a distinct type of biological damage that accumulates with age:

Primary Hallmarks (Direct Damage)

Hallmark Description Key Interventions
1. Genomic instability DNA damage accumulation from replication errors, ROS, UV, environmental toxins NAD+ precursors (PARP support), resveratrol/sirtuins, DNA repair optimization
2. Telomere attrition Chromosome end shortening with each cell division Exercise, stress reduction, epitalon (Russian), astragalus
3. Epigenetic alterations DNA methylation changes, histone modifications, loss of heterochromatin Caloric restriction, rapamycin, NAD+ precursors

Swipe table →

Antagonistic Hallmarks (Responses to Damage)

Hallmark Description Key Interventions
4. Loss of proteostasis Protein quality control decline; misfolded proteins accumulate Autophagy inducers (rapamycin, spermidine, urolithin A), heat shock
5. Deregulated nutrient sensing mTOR/AMPK/insulin/IGF-1 signaling disruption Rapamycin (mTOR), metformin (AMPK), caloric restriction, protein restriction
6. Mitochondrial dysfunction Energy production decline, ROS, metabolites Urolithin A, NAD+ precursors, CoQ10, exercise, cold/heat

Swipe table →

Integrative Hallmarks (Consequences of Above)

Hallmark Description Key Interventions
7. Cellular senescence "Zombie cells" accumulate, secrete SASP Senolytics: dasatinib + quercetin, fisetin, GLP-1 agonists
8. Stem cell exhaustion Regenerative capacity declines Rapamycin, growth hormone/IGF-1 modulation, exercise
9. Altered intercellular communication Inflammatory signaling, senescence-associated secretory phenotype (SASP) Senolytics, metformin, omega-3s, anti-inflammatory lifestyle

Swipe table →

The framework matters because it helps explain why interventions work — and why combination therapy targeting multiple hallmarks is likely more effective than any single intervention.

1. Senolytics — Clearing Zombie Cells

Senescent cells resist apoptosis and secrete the SASP (pro-inflammatory cytokines, growth factors, proteases), creating a pro-inflammatory, pro-cancer microenvironment.

The senolytic strategy: Selectively induce apoptosis in senescent cells while leaving healthy cells intact.

Senolytic Mechanism Evidence Level Notes
Dasatinib + Quercetin (D+Q) Dasatinib: kinase inhibitor; Quercetin: senolytic flavonoid; synergistic Moderate (early human trials) Best-studied combination;间歇性 dosing
Fisetin Multiple mechanisms; strong in vitro data Moderate 20mg/kg in mice = ~150mg human; natural polyphenol
Quercetin alone Weaker senolytic than D+Q or fisetin Lower May work better as adjuvant
Navitoclax Bcl-2 family inhibitor Early Not clinically available
FOXO4-DRI p53 pathway inhibitor Preclinical only Peptide; not clinically available

Swipe table →

Evidence status: Phase 2 human trials in idiopathic pulmonary fibrosis (IPF) and diabetic kidney disease show senolytics reduce senescent cell burden. IPF trial showed improved physical function (6-minute walk distance) in 11/14 participants. Safety profile acceptable with intermittent dosing.

Important caveats: - Long-term safety unknown (senescent cells have tumor suppression function) - Biomarkers of senescence burden not yet standardized for clinical use - Dosing is still being refined

See Senolytics for detailed protocols.

2. mTOR Inhibition — The Rapamycin Case

mTOR (mechanistic target of rapamycin) is the master nutrient-sensing kinase that: - Activates protein synthesis (growth) - Inhibits autophagy (cellular cleaning) - Drives cellular senescence and SASP

Rapamycin (sirolimus) is an mTOR inhibitor originally used as an immunosuppressant transplant drug. It is the most effective pharmacological longevity intervention in model organisms (yeast, worms, flies, mice).

Mouse data: Rapamycin extends median lifespan 10-26% in mice even when started at the equivalent of 60 human years. It improves cardiac function, cognitive function, immune function, and reduces multiple age-related pathologies simultaneously.

Human data: No RCTs for longevity indication yet. Off-label use is widespread in the longevity community. The TAME (Targeting Aging with Metformin) trial will test metformin, rapamycin, and other interventions as combination therapy.

See Rapamycin Dosing Protocols and Metformin and Rapamycin for detailed protocols and evidence evaluation.

3. Autophagy Enhancement

Autophagy ("self-eating") is the cellular recycling process that clears damaged organelles, misfolded proteins, and intracellular pathogens. It declines with age, allowing damage to accumulate.

Autophagy inducers:

Compound Mechanism Evidence
Rapamycin/sirolimus mTOR inhibition Strong (pharmacological)
Spermidine mTOR inhibition; autophagy gene activation Moderate (epidemiological + preclinical)
Urolithin A Mitophagy (mitochondrial autophagy) Moderate (human RCTs)
Resveratrol Sirtuin activation → autophagy Moderate (preclinical dominant)
Fasting (16+ hours) AMPK activation, insulin drop Strong (mechanistic)
Exercise AMPK activation, autophagy induction Strong

Swipe table →

The fasting connection: The most powerful natural autophagy inducer is fasting — 16+ hours without food. Overnight fasting (12-14 hours) produces some autophagy; 24-48 hour fasts produce more dramatic effects. The protein signaling (leucine, mTOR) must drop sufficiently.

See Autophagy for detailed protocols.

4. NAD+ Restoration

NAD+ declines ~50% from age 20 to 50. It's the central cofactor for: - Sirtuins (1-7) — deacetylases linked to mitochondrial biogenesis, DNA repair, stress resistance - PARPs — DNA repair enzymes; chronic DNA damage consumes NAD+ - CD38/CD157 — ectoenzymes that degrade NAD+; rise with inflammation/aging

See NAD+ and Sirtuin Activators and NAD+ IV Therapy.

5. Metformin

The most widely prescribed type 2 diabetes drug, with potential longevity benefits:

Aspect Details
Mechanism AMPK activation, mTOR inhibition, reduced insulin/IGF-1 signaling, anti-inflammatory
Evidence T2D patients on metformin show reduced all-cause mortality and cancer incidence in observational studies
TAME trial Targeting Aging with Metformin — multi-arm trial targeting aging biomarkers
Dosing —
Pros Cheap, well-understood safety, available, good evidence for diabetes
Cons GI side effects, B12 deficiency, not as potent as rapamycin for longevity

Swipe table →

See Metformin and Rapamycin for detailed comparison.

Evidence Level by Intervention

Intervention Preclinical Evidence Human Evidence Clinical Status
Rapamycin Very strong (lifespan in multiple species) Off-label use; no RCTs yet Experimental for longevity
Metformin Moderate Observational (T2D); TAME trial underway Approved for T2D; off-label common
Senolytics (D+Q, fisetin) Strong Early phase human trials Experimental
NMN/NR Strong Small human studies (NAD+ elevation) Supplements; no FDA approval
Urolithin A Moderate Human RCTs (gut, muscle) Supplement available
Spermidine Moderate Epidemiological (dietary) + some trials Supplement; dietary sources
Autophagy (fasting/exercise) Very strong Extensive observational Widely practiced
Epitalon Moderate Limited Russian human studies Not FDA-approved; supplement
Telomerase activation Limited No proven human telomere lengthening Controversial

Swipe table →

Uses

The longevity field is prone to extreme recommendations. The practical hierarchy:

Step 0: Measure baseline - Blood work: CBC, metabolic panel, lipids, HbA1c, fasting insulin, vitamin D, hs-CRP - Consider: epigenetic age (Horvath clock), telomere length (controversial) - Physical: VO2max, body composition (DEXA), grip strength

Biomarkers to Track

Category Biomarkers Frequency
Metabolic Fasting insulin, HbA1c, triglycerides, HDL 2x/year
Inflammatory hs-CRP, IL-6, TNF-α 1-2x/year
Cardiovascular Lp(a), ApoB, homocysteine 1x/year
Body composition DEXA scan 1x/year
Fitness VO2max, grip strength 1x/year
Epigenetic Epigenetic age clocks 1x/year
Organ-specific Kidney function, liver enzymes 2x/year

Swipe table →

Connection to Other Sections

Notes

The longevity field has moved from fringe to mainstream in the past decade, but human evidence for most interventions lags far behind animal evidence. The strongest human evidence is for: 1. Exercise (Zone 2 + strength) — no supplement comes close 2. Sleep — glymphatic clearance is nightly maintenance 3. Rapamycin — despite no human RCTs, the mechanism is compelling and animal data is overwhelming 4. Metformin — usable now for those with metabolic dysfunction; TAME trial will clarify

The most promising near-term clinical developments: - TAME trial results (expected 2026-2027) - GLP-1 agonists (semaglutide) for obesity/mortality - Senolytic Phase 3 trials (IPF, kidney disease) - Epigenetic reprogramming ( Altos Labs, Calico)

The biggest risks in the longevity space: - Supplement hype exceeding evidence (NR/NMN pricing >> evidence) - Pharma-industry capture of "longevity" as a marketing term - Unregulated "longevity clinics" selling expensive, unproven protocols - Ignoring the foundations (exercise, sleep, diet) for expensive interventions

09Connections

Neighborhood · 8 linked entriesOpen full map →
Mitochondrial healthMechanism · 34 links→ NAD+Compound · 32 links→ Therapeutic peptidesGuide · 30 links→ AutophagyMechanism · 21 links→ Biohacking and optimizationGuide · 21 links→ mTOR and AMPKMechanism · 21 links→ Peptide bioregulators (Khavinson)Compound · 21 links→ SenolyticsCompound · 20 links→

10Sources

  1. PubMed 6773612PubMed 6773612
  2. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell . 2023 Jan 19;186(2):243-278. PMID 36599349PubMed 36599349
  3. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber WA. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open . 2018;1(6):e183605. PMID 30646320PubMed 30646320
  4. PubMed 19349377PubMed 19349377
  5. PubMed 20469800PubMed 20469800
  6. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med . 2010;7(7):e1000316. PMID 20668659PubMed 20668659
  7. Moel M, et al. PEARL trial. Aging (Albany NY) . 2025;17(4):908-936. PMID 40188830PubMed 40188830
  8. Stanfield B, et al. RAPA-EX-01. J Cachexia Sarcopenia Muscle . 2026;17(2):e70274. PMID 41985884PubMed 41985884
  9. PubMed 40582648PubMed 40582648
  10. Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis. EBioMedicine . 2019;40:554-563. PMID 30678418PubMed 30678418
  11. Fahy GM, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell . 2019;18(6):e13028. PMID 30676660PubMed 30676660
  12. Horvath S. DNA methylation age of human tissues. Genome Biol . 2013;14(R115). PMID 24138928PubMed 24138928
  13. PubMed 29676998PubMed 29676998
  14. Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging . 2019;11(2):303-327. PMID 30669119PubMed 30669119
  15. PubMed 35021509PubMed 35021509
  16. PubMed 25215462PubMed 25215462
  17. Tartiere AG, Freije JMP, López-Otín C. The hallmarks of aging as a conceptual framework for health and longevity research. Front Aging . 2024;5:1334261. doi 10.3389/fragi.2024.1334261DOI 10.3389/fragi.2024.1334261
  18. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metab . 2016;23(6):1060-1065. PMID 27304507PubMed 27304507

11Entry history

Latest content update.

Folded in 1 earlier page: longevity-and-anti-aging-index.

Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.